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Abstract
Background: A better anti-malarial efficiency and lower neurotoxicity have been reported for mefloquine (MQ) (+)-
enantiomer. However, the importance of stereoselectivity remains poorly understood as the anti-malarial activity of
pure enantiomer MQ analogues has never been described. Building on these observations, a series of enantiopure
4-aminoalcohol quinoline derivatives has previously been synthesized to optimize the efficiency and reduce
possible adverse effects. Their in vitro activity on Plasmodium falciparum W2 and 3D7 strains is reported here along
with their inhibition of b-haematin formation and peroxidative degradation of haemin, two possible mechanisms
of action of anti-malarial drugs.
Results: The (S)-enantiomers of this series of 4-aminoalcohol quinoline derivatives were found to be at least as
effective as both chloroquine (CQ) and MQ. The derivative with a 5-carbon side-chain length was the more
efficient on both P. falciparum strains. (R )-enantiomers displayed an activity decreased by 2 to 15-fold as compared
to their (S) counterparts. The inhibition of b-haematin formation was significantly stronger with all tested
compounds than with MQ, irrespective of the stereochemistry. Similarly, the inhibition of haemin peroxidation was
significantly higher for both (S) and (R)-enantiomers of derivatives with a side-chain length of five or six carbons
than for MQ and CQ.
Conclusions: The prominence of stereochemistry in the anti-malarial activity of 4-aminoalcohol quinoline
derivatives is confirmed. The inhibition of b-haematin formation and haemin peroxidation can be put forward as
presumed mechanisms of action but do not account for the stereoselectivity of action witnessed in vitro.
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Background
Mefloquine (MQ) is a quinoline methanol derivative
with a high schizontocide activity against Plasmodium
species. This molecule possesses two asymmetric carbon
atoms (Figure 1) and a long half-life (circa 14 days)
[1,2]. The latter propriety can be seen as a therapeutic
advantage as a lower rate of relapses has been reported
for anti-malarials with long half-lives [3]. Additionally, it
also allows a weekly administration, making MQ a good
candidate for long-term prophylactic treatments through
improved compliance [4]. Despite an overall acceptable
tolerability, dose-related neuropsychiatric adverse effects
can occur [4,5], therefore, contraindicating MQ in indi-
viduals with a history of epilepsy or psychiatric disease.
The opening of the piperidine ring at the 4-position of
the quinoline scaffold was reported to yield molecules
with a better potency and a lesser neurotoxicity than
that of MQ [6]. The same team recently described a ser-
ies of MQ non-piperidine analogs displaying a lower
penetration in the brain than MQ along with a similar
metabolic stability [7]. Another way to reduce neuro-
toxicity of MQ derivatives could be the synthesis of
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Indeed, although MQ is commercially available as a
racemic mixture of its erythro enantiomers, previous
w o r k ss h o w e dt h a te n a n t i o m e r i s mc o u l dp l a yap a r ti n
the in vitro activity and toxicity of the drug. IC50 values
for the (+)-enantiomer of MQ were found to be lower
than those of the (-)-enantiomer by a factor of 1.6-1.8
on some strains (D6 and W2) [8] although no difference
was found on other strains (L-3 and FCM29) [9]. As
regards toxicity, the (-)-enantiomer was found to block
to central nervous system adenosine receptors, while the
(+)-enantiomer did not. This blockage of central adeno-
sine receptors by the (-)-enantiomer is believed to result
in neuropsychiatric symptoms associated with MQ [10].
With these differences in activity and toxicity in mind,
a new enantioselective pathway to synthesize pure enan-
tiomers of MQ amino-analogs was recently proposed
[11,12]. In this paper, the in vitro anti-malarial activity
on Plasmodium falciparum strains of a series of these
enantiomers is reported as well as their effect on
b-haematin formation and peroxidative-degradation of
haemin, two mechanisms of action likely involved in the
anti-malarial activity of 4-aminoquinolines [13].
Methods
Enantioselective synthesis of 4-aminoalcohol quinoline
derivatives
All starting materials and reagents were obtained from
commercial suppliers and were used without further
purification. Reactions requiring anhydrous conditions
were performed under a blanket of argon. All solvents
were purified via literature procedures or used without
further purification. 4-aminoalcohol quinoline deriva-
tives synthesized are represented in Table 1. They were
synthesized following the general procedure described
by Jonet et al. [11,12].
Plasmodium falciparum susceptibility assays
The in vitro activities our series of 4-aminoalcohol
derivatives were tested over a concentration range of
0.78-400 nM against P. falciparum strains W2 and 3D7.
These strains are resistant or susceptible to CQ, respec-
tively. Additionally, W2 is sensitive while 3D7 displays a
decreased susceptibility to MQ. The traditional labelled
hypoxanthine method was used to assess anti-malarial
activity, as described by Desjardins et al. [14]. CQ and
MQ were routinely included as positive controls as well
as negative controls using solvent. The resulting IC50s
were calculated using Pk-Fit software [15]. Growth inhi-
bition (I) and corresponding drug concentrations (C)
were fitted according to a sigmoid model, described as:
I=

Imax.Cγ

/

Cγ +I C 50γ

where Imax is the maximum growth inhibition and
gamma the sigmoid factor of the curve.
Inhibition of b-haematin aggregation
All chemicals were purchased from Sigma-Aldrich
(Saint-Quentin Fallavier, France). The inhibition of
b-haematin formation was tested using the technique by
Baelmens et al. [16]. CQ and MQ were included in each
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Figure 1 Chloroquine and mefloquine enantiomers.
Table 1 4-aminoalcohol quinoline derivatives
R
Butyl (R)-1 (S)-1
Pentyl (R)-2 (S)-2
Hexyl (R)-3 (S)-3
Heptyl (R)-4 (S)-4
Octyl (R)-5 (S)-5
Phenyl (R)-6 (S)-6
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Page 2 of 7series of experiments as controls. Briefly, 100 μLo fa
fresh 6.5 mM solution of haemin dissolved in 0.2 M
NaOH was mixed with 100 μL of 3 M sodium acetate,
25 μL of 17.4 M acetic acid and 25 μLo ft h et e s t e d
drug or relevant solvent as negative control. Stock solu-
tions (20 mM) of CQ were prepared in water while MQ
and 4-aminoalcohol quinoline derivatives were solubi-
lised in MeOH/DMSO (4/1, v/v). Inhibition experiments
were typically carried out over a concentration range of
0-2 mM (final concentration of the drug in wells). After
a 24 h-incubation at 37°C under shaking, the superna-
tant resulting from centrifugation for 15 min at 3,300 g
was discarded and the pellet washed with 200 μL
DMSO. This latter step was repeated once and, after a
final wash with water, the pellet was dissolved in 200 μL
0.1 M NaOH. After a further 1:30 dilution, absorption
at 405 nm was read using a Multiskan EX multiplate
reader (Thermo Labsystems, Issy les Moulineaux,
France). Results are expressed as percentage of inhibi-
tion of b-haematin formation as compared to the rele-
vant negative control result. Experiments were carried
out at least in triplicate and, when achievable, IC50s
were determined graphically.
Inhibition of hydrogen peroxide-mediated haemin
degradation
The monitoring of the peroxidative decomposition of
haemin was carried out as previously described [17].
The reactions were performed either in sodium acetate
0.2 M (pH = 5.2) or HEPES 0.2 M (pH = 7.0). These
values were chosen because the former is thought to be
within the pH range of P. falciparum digestive vacuole
and the latter within the pH range outside the food
vacuole of the parasite. For inhibition assessments, stock
solutions (1.2 mM) of CQ was prepared in the relevant
buffer while stock solutions of MQ and 4-aminoalcohol
quinoline derivatives were made in a mixture of MeOH/
DMSO (4/1, v/v). The final concentration of drugs in
wells was 100 μM. Additionally, to account for a possi-
ble shift in absorption due to the solvent, positive con-
trol curves were done using either water or MeOH/
DMSO. The peroxidative reaction was initiated by the
addition of 20 μLH 2O2 (200 mM) and followed by mea-
suring the decrease in absorption at the Soret band (405
nm) at 30 and 60 min using a Multiskan EX multiplate
reader. Negative controls (with addition of H2Oi n s t e a d
of H2O2) were also included in each experiment. Results
are expressed as the percentage of unchanged haemin in
the solution at the various time points.
Statistical analysis
Each experimental condition was held in triplicate.
Results are given as mean ± standard deviation of values
obtained from at least three independent experiments.
Comparisons of percentages of b-haematin inhibition
or remaining haemin (peroxidative degradation of hae-
min) were made using the Mann-Whitney signed rank
test of Vassarstats website [18]. Statistical significance
was defined as p < 0.05.
Results
Plasmodium falciparum susceptibility
IC50s for the various products are reported in Table 2.
Interestingly, enantiomers with a (S)-absolute configura-
t i o nw e r ef o u n dt ob em o r ea c t i v et h a nt h e i r( R)-coun-
terparts by a factor ranging from two to 15-fold,
according to the compound and the strain considered
(Table 2). Compound (S)-2 was the more active of all,
whatever the strain tested, followed by (S)-3 and (S)-1.
Compounds (S)-4,( S)-5 and (S)-6 displayed similar
IC50s, around 30 nmol/L. All (S)-enantiomers displayed
lower IC50s than the racemic mixture of MQ, whatever
the strain. Additionally, some IC50 values of (S)-enantio-
mers were also below or equivalent to those of CQ for
the 3D7 strain.
Inhibition of b-haematin formation
Global and enantiomer specific percentages of inhibition
are reported in Table 3. All 4-aminoalcohol quinoline
derivatives displayed a significantly higher inhibition of
b-haematin formation than MQ while CQ was signifi-
cantly more efficient at inhibiting the process than all
other compounds tested. Without reference to the abso-
lute carbon configuration, compounds 4 and 5 were
more potent than all the others (p < 0.002 and p < 0.02,
respectively). No statistically significant differences were
Table 2 In vitro antimalarial activity of 4-animoalcohol
quinoline enantiomers
Compound IC50
a (nmol/L) R/S ratio
W2 3D7 W2 3D7
Chloroquine 572 ± 112 25.7 ± 7.81 - -
Mefloquine 26.5 ± 2.44 52.2 ± 4.18 - -
(R)-1 ND
b 27.8 ± 1.42 ND 2.19
(S)-1 ND 12.7 ± 0.67
(R)-2 38.2 ± 3.63 74.7 ± 4.71 6.47 8.97
(S)-2 6.98 ± 0.62 8.33 ± 0.44
(R)-3 142 ± 11.2 205 ± 16.2 15.1 14.1
(S)-3 9.40 ± 0.91 14.5 ± 1.23
(R)-4 ND 254 ± 26.9 ND 7.70
(S)-4 ND 33.0 ± 1.55
(R)-5 ND 290 ± 43.8 ND 9.32
(S)-5 ND 31.1 ± 0.93
(R)-6 41.1 ± 9.62 104.5 ± 9.72 2.15 2.98
(S)-6 19.1 ± 4.03 35.1 ± 3.55
a: Results expressed as mean ± standard deviation
b: Not Determined
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Page 3 of 7found between the different (R)o r( S)-enantiomer 4-
aminoalcohol quinoline derivatives except for compound
2 f o rw h i c ht h e( R)-enantiomer was found to be slightly
more active than its counterpart (p = 0.0477). b-haema-
tin formation was significantly lower with compound
(R)-4 than with all other compounds except for (S)-4,
(R)-5 and (S)-5. Additionally, enantiomer (S)-4 had a
significantly stronger inhibitory activity than (R)-1,( S)-1,
(S)-2,( R)-3 and (R)-6.
Inhibition of the peroxidative degradation of haemin
At pH 5.2, within the pH range of the food vacuole,
unchanged haemin values were significantly lower for
the MeOH/DMSO positive control after a 30 min incu-
bation but not after 60 min, as compared to the water
control (Table 4). When enantiomers sharing the same
side-chain length were compared, no significant differ-
ence was witnessed. Compounds 2, 3 and 6 were all
more efficient in preventing haemin peroxidation than
MQ, CQ and compounds 1, 4 and 5 after a 30-min
incubation, except for (R)-2 for which values were not
statistically different from those of (S)-5.A t6 0m i n ,t h e
same differences held (p < 0.0424) except for 2,f o r
which no difference was found with CQ activity, for (S)-
2, for which values were similar to those of compounds
4 and 5, as were the values for compounds 5 and 6.
Within the more efficient compounds, no significant
difference of activity was found between compounds 3
and 6 while compound 2 showed a better protection of
haemin against peroxidation than both compounds 3
(p ≤ 0.0006) and 6 (p ≤ 0.0151).
At pH 7.0, results were close to those witnessed at pH
5.2 [see Additional file 1]. The significant difference
between MeOH/DMSO and water positive controls per-
sisted throughout the 60-min incubation. Once more,
no significant difference was found between enantiomers
sharing the same side-chain and 4-aminoalcohol quino-
line derivatives were generally more efficient than MQ
and CQ at inhibiting this haemin degradation pathway.
Table 3 Global and enantiomer specific inhibition of b-
haematin aggregation
Compound Inhibition
(%)
Enantiomer Inhibition
(%)
IC50
(mM)
CQ
index
a
Chloroquine 77.8 ±
6.27
b
-N A
c 0.85 ±
0.11
-
Mefloquine 6.1 ± 4.63 - ND
d >>>2 >>>
2.35
1 47.1 ± 7.84 (R) 49.8 ± 7.54 > 2 > 2.35
(S) 44.7 ± 7.58 > 2 > 2.35
2 49.1 ± 6.23 (R) 51.2 ± 7.03 1.90 ±
0.26
2.23
(S) 46.5 ± 4.1 > 2 > 2.35
3 50.2 ± 5.05 (R) 48.3 ± 3.68 > 2 > 2.35
(S) 51.8 ± 5.60 1.90 ±
0.21
2.23
4 59.3 ±
6.27*
(R) 60.8 ± 6.44 1.61 ±
0.17
1.89
(S) 57.8 ± 6.07 1.29 ±
0.13
1.52
5 57.6 ±
8.31**
(R) 53.6 ± 8.89 1.86 ±
0.31
2.19
(S) 61.7 ± 5.48 1.77 ±
0.16
2.08
6 50.6 ± 7.63 (R) 49.0 ± 7.95 > 2 > 2.35
(S) 52.2 ± 7.38 1.92 ±
0.27
2.26
a: calculated as compound IC50/chloroquine IC50
b: Results expressed as mean ± standard deviation of the inhibition witnessed
for each compound at a 2 mM concentration.
c: Not applicable
d: Not determined
*: Significantly higher than all other values in the same column except for
chloroquine and compound 4 (p ≤ 0.0011)
**: Significantly higher than values for mefloquine and compounds 1, 2, 3 and
6 (p < 0.02)
Table 4 Peroxidative degradation of haemin at pH 5
Compound Unchanged haemin (%)
30 min 60 min
Negative control Water 98 ± 6.0
a 93 ± 5.9
MeOH/DMSO 98 ± 1.0 97 ± 1.3
Positive control Water 45 ± 7.0 36 ± 5.3
MeOH/DMSO 41 ± 6.2* 33 ± 4.5
Chloroquine 53 ± 10.6 45 ± 8.5
Mefloquine 48 ± 9.1 39 ± 7.2
(R)-1 46 ± 7.3 39 ± 4.9
(S)-1 47 ± 7.8 40 ± 5.0
(R)-2 63 ± 2.8** 48 ± 3.6***
(S)-2 63 ± 4.1** 49 ± 3.8
†
(R)-3 73 ± 2.4
‡ 60 ± 2.7
‡
(S)-3 73 ± 2.0
‡ 59 ± 2.9
‡
(R)-4 50 ± 12.7 45 ± 12.7
(S)-4 49 ± 12.1 45 ± 11.1
(R)-5 49 ± 11.1 44 ± 11.3
(S)-5 50 ± 13.5 45 ± 14.3
(R)-6 71 ± 2.6
$ 57 ± 3.9
£
(S)-6 70 ± 4.6
$ 56 ± 4.5
£
a: results given as mean ± standard deviation
*: significantly lower values than water positive control ones at the same time
point (p ≤ 0.0124)
Significantly higher values at the same time point than those of:
**: chloroquine, mefloquine and compounds (R)-1, (S)-1, (S)-4, (R)-4, (R)-5, (S)-5
(p ≤ 0.0357)
***: mefloquine and compounds (R)-1, (S)-1, (R)-4, (S)-4, (R)-5, (S)-5 (p ≤ 0.0357)
†: mefloquine and compounds (R)-1, (S)-1 (p ≤ 0.0012)
‡: chloroquine, mefloquine and all other compounds but (R)-6 and (S)-6 (p ≤
0.0006)
$: chloroquine, mefloquine and compounds (R)-1, (S)-1, (R)-4, (S)-4, (R)-5, (S)-5
(p ≤ 0.0025)
£: chloroquine, mefloquine and compounds (R)-1, (S)-1, (R)-4, (S)-4 (p ≤ 0.0424)
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more efficient.
Discussion
The in vitro anti-malarial activity of this series of 4-ami-
noalcohol quinoline enantiomers is reported here for
the first time. Previously, only the activity of a racemic
mixture of compound 1 has been described [7]. It was
reported to have an IC90 of 32 nmol/L on P. falciparum
strain TM90C2A, resistant to CQ and MQ. In the pre-
sent work, the activities of compounds (R)-1 and (S)-1
were evaluated on P. falciparum strain 3D7, displaying a
reduced susceptibility to MQ (IC50 above 50 nmol/L).
Compound (S)-1 was found to have an IC50 of 12.7
nmol/L while (R)-1 displayed a two-fold higher IC50.
Corresponding IC90sf o r( S)-1,( R)-1 and MQ were
respectively 36.0, 55.3 and 90.0 nmol/L, which is consis-
tent with the previous report. However, the best anti-
malarial activity in this series was witnessed for com-
pound (S)-2, carrying a side-chain with 5 carbons, both
on 3D7 and W2 strains, followed by compounds (S)-1
and (S)-3. Interestingly, (S)-enantiomers were found to
be more active on both W2 and 3D7 P. falciparum
strains than their counterparts, whatever the side-chain
length. The (S)-enantiomer of MQ has previously been
described as having a better in vitro activity than the
(R)-one by a ratio close to 2-fold [8]. The results
obtained with our series of 4-aminoalcohol quinolines
indicate that this ratio would at least be of 2-fold and
could reach up to 15-fold. These results also further
back up the prominence of the absolute carbon config-
u r a t i o ni nt h ein vitro activity of this type of chemical
structures. However, further tests on additional P. falci-
parum strains or isolates would help ascertain this pro-
minence and its magnitude, as another study previously
cast doubt on the impact of enantiomerism on the in
vitro anti-malarial activity of MQ [9].
The molecular mechanism of action of MQ and 4-
aminoalcohol quinolines is still poorly understood [13].
Some authors have suggested that the mechanism of
action of these molecules could be similar to that of CQ
[19,20]. To try to understand the mechanism underlying
the enantiomeric specificity of action, we therefore
chose to focus on investigating the possible inhibition of
haem detoxification by 4-aminoalcohol quinolines.
Indeed, compounds like CQ are thought to act through
the inhibition of b-haematin formation, leading to a
toxic accumulation of haem (ferriprotoporphyrin IX) in
the parasite’s food vacuole [21]. Alternatively, inhibition
of the peroxidative degradation of haemin has also been
proposed as a possible additional mechanism of action
for quinolines and other molecules with anti-malarial
properties [22,23]. Nevertheless, it has to be kept in
mind that, despite a closely related structure, MQ has
been described as less efficient in inhibiting b-haematin
formation [23,24]. All compounds described in this
paper displayed a better inhibitory activity on b-haema-
tin formation than that of MQ, whatever the enantiomer
and the side-chain length. However, these activities were
significantly lower than that of CQ. Therefore, the better
in vitro activity of our compounds as compared to CQ,
cannot be accounted for by this sole mechanism of
action. An interesting point to underline is that the
longer the side-chain, the better the inhibitory activity
was on this degradation pathway. Compounds 4 and 5
were indeed the more efficient in inhibiting b-haematin
formation but were less active in vitro than compounds
1, 2 or 3 on P. falciparum strains. Additionally, the
results obtained on this pathway do not account for the
discrepancies between the in vitro activity of 4-aminoal-
cohol quinoline enantiomers, as no significant difference
was found in the activity of enantiomers with the same
side-chain length. Stereochemistry is therefore unlikely
to hinder the linkage of these compounds to the ferri-
protoporphyrin IX structure, which is thought to be a
pre-requisite for a good inhibition of b-haematin forma-
tion [25,26].
As regards the peroxidative degradation of haemin, no
difference in the activity of enantiomers sharing the
same side-chain length was once more witnessed. More-
over, no major difference between results obtained at
pH 5.2 and 7.0 were highlighted. This is consistent with
the fact that all of the tested molecules would mainly be
monoprotonated at either pH, as all of them display cal-
culated pKa1 values below 2.0 and pKa2 values above
7.8. Therefore, their reactivity would be the same inside
as outside the food vacuole. Nevertheless, the most effi-
cient compounds were compounds 2, 3 and 6 this time.
Hence, inhibition of haemin peroxidation results display
a better correlation with the anti-malarial activity wit-
nessed in vitro than the one observed with b-haematin.
On the whole, although this series of 4-animoalcohol
quinoline derivatives yielded better results than MQ on
the possible mechanisms of action investigated in this
paper, these mechanisms did not provide a rationale for
the enantiomer-dependent in vitro activity of our com-
pounds. Another explanation, not necessarily exclusive
of the mechanisms of action explored above, has to be
sought to explain the selective in vitro activity of S-
enantiomers. Such a hypothesis could be (i) another
(additional) target of action in the parasite like the inhi-
bition of an enzyme of P. falciparum , as stereoselectiv-
ity has previously been shown as important for some
enzymatic interactions [27,28] or (ii) a differential active
transport mechanism that would preferentially allow the
passage of one of the enantiomers at the site of action
of our molecules. The latter hypothesis sounds attractive
as P. falciparum protein Pgh-1 (also termed PfMDR1),
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encoded by pfmdr1 , is mainly present on the food
vacuole membrane and thought to transport anti-malar-
ial drugs such as MQ in the food vacuole where they
inhibit the formation of b-haematin [29,30].
Alternatively, Pgh1 could also be the primary target of
MQ and 4-aminoquinoline activities through a direct
inhibition of its transporter function, which has been
demonstrated for quinine and halofantrine [31]. This
would explain the reduced susceptibility to MQ of
strains overexpressing pfmdr 1p u tf o r w a r db ys o m e
authors. However, the link between overexpression of
pfmdr 1 and MQ resistance remains debatable, as
shown with case reports from Asian isolates [32,33]. As
regards stereoselectivity, it has indeed been shown for
another active transporter belonging to the same P-gly-
coprotein family and situated on the blood-brain barrier
that MQ enantiomers displayed differential behaviours
towards its activity as the (-)- 11S-2’R MQ was found to
preferentially accumulate in the brain [34,35]. Therefore,
if such a stereoselective mechanism existed for Pgh-1
transport of this series of compounds, the preferential
accumulation of (S)-enantiomers in the food vacuole
w h e r et h e yw o u l di n h i b i th aem detoxification could
explain their better activity as compared to (R)-
enantiomers.
Conclusions
In this paper, some molecules in a series of enantiomeri-
cally pure 4-aminoalcohol quinoline derivatives were
shown to display a stronger anti-malarial activity (within
the nanomolar range) than MQ and/or CQ. Moreover,
(S)-enantiomers were shown to be more potent than
their counterparts by a 2-15-fold ratio. As regards their
mechanism of action, both (S)e n d( R)-molecules were
shown to more strongly inhibit b-haematin formation
than MQ as well as the peroxidative degradation of hae-
min for some of them. The better in vitro anti-malarial
activity of (S)-enantiomers could be accounted for by a
stereoselective specific transport in the food vacuole of
the parasite through Pgh-1 transporter. Further experi-
ments are warranted to confirm this hypothesis.
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